The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell
immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1) …

The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by …

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …

Over the course of past few years, cancer immunotherapy has been accompanied with
promising results. However, preliminary investigations with respect to immunotherapy …

PURPOSE Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always
fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Co-inhibitory receptors are important regulators of T-cell function that define the balance
between tolerance and autoimmunity. The immune regulatory function of co-inhibitory …

The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-
characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies …